The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Real-world data on brentuximab vedotin with chemotherapy in Hodgkin lymphoma
Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, presents the results of a retrospective analysis of the characteristics of patients with classical Hodgkin lymphoma receiving brentuximab vedotin with chemotherapy. Treatment with brentuximab vedotin, doxorubicin, vinblastine and dacarbazine (A+AVD) was shown to significantly improve progression-free survival (PFS) in patients with newly diagnosed classical Hodgkin lymphoma when compared to doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) in the Phase III ECHELON-1 study (NCT01712490). Data from 4259 patients was included in the retrospective analysis. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
